secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001104659-25-105185
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q3 revenue $1.1B (+13%), EPS $3.40 (+21%); raises FY2025 guidance
-----------------------------------------------------------------------

- Revenue $1,105M (+13% reported, +12% organic); CAG Diagnostics recurring revenue +11% reported, +10% organic.
- EPS $3.40 (+21% reported, +15% comparable); operating margin 32.1%, +100 bps reported.
- Raises FY2025 revenue guidance to $4,270-$4,300M (midpoint +$43M) and EPS guidance to $12.81-$13.01 (midpoint +$0.33).
- Over 1,700 IDEXX inVue Dx placements in Q3; strong capital instrument revenue growth of 74% reported.
- Updated FY2025 organic revenue growth outlook 8.8%-9.5%; comparable margin expansion guidance raised to 80-100 bps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465925105185/0001104659-25-105185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465925105185/tm2530045d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer